US.BIIB · Biogen

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.6290648259297638,
        "turnoverUsdM": 189.20417841507,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BIIB",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 205.6846,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 5.3,
      "take_profit_price": 229.9328,
      "target_multiplier": 1.9,
      "technical_strength": 1.78,
      "take_profit_percent": 5.9
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.2581296518595275,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 61.6,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 53.6,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 8
  },
  "market": {
    "ma20": 217.032,
    "ma50": 209.473,
    "close": 217.1,
    "prevClose": 215.43,
    "avgVolume20": 705555,
    "volumeRatio": 1.24,
    "changePercent": 0.78
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 8,
    "details": {
      "ret_5d": -0.03300512373636466,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 8,
      "vcp_bonus": 0,
      "vol_ratio": 1.23620644410874,
      "ret_points": 0,
      "vol_points": 4,
      "range_ratio": 0.9665862244661336,
      "volat_points": 0,
      "day_range_pct": 0.02324969952788113,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 61.6,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 44,
        "contribution": 2.2
      },
      {
        "raw": 10.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 54,
        "contribution": 10.8
      },
      {
        "raw": 8.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 54.67,
        "contribution": 8.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 17.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 59.33,
        "contribution": 17.8
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 53.6,
    "details": [
      "基本面分析總分: 2.2/5分",
      "資金流分析總分: 10.8/20分",
      "市場環境分析總分: 8.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 17.8/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.2,
      "資金流": 10.8,
      "市場環境": 8.2,
      "情緒分析": 6,
      "技術信號": 17.8,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 189.20417841507,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 1.6,
          "obvPoints": 2.4,
          "vwapPoints": 2.4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BIIB",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 2.8,
            "details": {
              "qqq": {
                "ma20": 715.6679992,
                "ma50": 710.4063990999997,
                "name": "QQQ",
                "close": 714.88,
                "points": 1.4
              },
              "spy": {
                "ma20": 766.87899445,
                "ma50": 758.61640102,
                "name": "SPY",
                "close": 764.28998,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.6290648259297638,
          "atrPoints": 3,
          "cciPoints": 2.4,
          "vixPoints": 0,
          "marketTrendPoints": 2.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142028243,
                "url": "https://finnhub.io/api/news?id=23a6a88025c63f6fe8b732aeed19a55023244d6f9a9b7f89bb4cf83745ff3073",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 9:30 AM EDTCompany ParticipantsRobin Kramer - Executive VP & CFOAdam...",
                "category": "company",
                "datetime": 1788967624,
                "headline": "Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141397461,
                "url": "https://finnhub.io/api/news?id=eb28a911a812ba2af9d8b179d4f4eed9a7ee9fcb76668966482c6da35263a38d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...",
                "category": "company",
                "datetime": 1788433589,
                "headline": "Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients"
              },
              {
                "id": 141394954,
                "url": "https://finnhub.io/api/news?id=524fbdbda91a95f14d9f786fac930f2f05cbfe9c30cd36950b12849b6e72bdd1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track...",
                "category": "company",
                "datetime": 1788405959,
                "headline": "Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data"
              },
              {
                "id": 141377242,
                "url": "https://finnhub.io/api/news?id=defda5ae25192c577dc34362b616a6cb78f5530085da1d35dd943ffd5f65d1af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026. The deal lands just over a week after the company posted a second-quarter beat that sent shares up nearly 5% on July 29. Together, the two moments […]",
                "category": "company",
                "datetime": 1788338886,
                "headline": "Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet"
              },
              {
                "id": 141364572,
                "url": "https://finnhub.io/api/news?id=96292ea7f36033259878043ccf8aaadc836dcd4c68f80e3e939c8db3da56d144",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1787934624,
                "headline": "Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?"
              },
              {
                "id": 141329614,
                "url": "https://finnhub.io/api/news?id=15b14cc122e7278df19a5f71f7a060941112438e995ca19289366a9eef9bddee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 14.4% to $218.22 per share while the index has gained 10.5%.",
                "category": "company",
                "datetime": 1787668724,
                "headline": "3 Reasons to Sell BIIB and 1 Stock to Buy Instead"
              },
              {
                "id": 141283040,
                "url": "https://finnhub.io/api/news?id=04014bc83df161e7f0b6800ceedd32afeed42773d4152055002ca69c2a5b6820",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. See our latest analysis for Biogen. Biogen's recent guidance upgrade comes after a period of renewed momentum, with the share price at US$214.35 and a 30 day share price return of about 8%, while the 1 year total shareholder return of around 54% contrasts with weaker 3 and 5 year total shareholder returns. This...",
                "category": "company",
                "datetime": 1787335779,
                "headline": "Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?"
              },
              {
                "id": 141283041,
                "url": "https://finnhub.io/api/news?id=b2e149fa6cfa0bb8923289db5380e452ecc38c942fc78fbc0bd6688fe7eaa233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio. This improved outlook, combined with investor attention on five upcoming Phase 3 readouts in lupus, transplant, and rare disease programs, has become a central focus in reassessing the company’s long-term profile. Next, we’ll examine how Biogen’s higher earnings guidance and advancing...",
                "category": "company",
                "datetime": 1787321617,
                "headline": "What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders"
              }
            ],
            "raw_source": [
              {
                "id": 142064393,
                "url": "https://finnhub.io/api/news?id=7c28e78d9040a5cce97fe2b77384836940d53d535f5f71724541cccc657ad8ee",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1789067101,
                "headline": "Thursday's session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 142062921,
                "url": "https://finnhub.io/api/news?id=1b80e9f9427e9c3035cd79ef8259c978d6b44275234f1f81e6e731c107c4638d",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "HSBC  analyst Rajesh Kumar   maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.",
                "category": "company",
                "datetime": 1789034979,
                "headline": "HSBC Maintains Reduce on Biogen, Raises Price Target to $175"
              },
              {
                "id": 142028243,
                "url": "https://finnhub.io/api/news?id=23a6a88025c63f6fe8b732aeed19a55023244d6f9a9b7f89bb4cf83745ff3073",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 9:30 AM EDTCompany ParticipantsRobin Kramer - Executive VP & CFOAdam...",
                "category": "company",
                "datetime": 1788967624,
                "headline": "Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 142027055,
                "url": "https://finnhub.io/api/news?id=dc8445d3883f5ff997b89b57d37c948989570783e55e47f5348040b705b751c6",
                "image": "https://image.cnbcfm.com/api/v1/image/108360508-17889676501788967647-48272413107-1080pnbcnews.jpg?v=1788967649&w=1920&h=1080",
                "source": "CNBC",
                "related": "BIIB",
                "summary": "Biogen CEO Christopher Viehbacher joins 'Squawk on the Street' to discuss their upcoming product pipeline, developments in Alzheimer treatment and medication and more.",
                "category": "company",
                "datetime": 1788954406,
                "headline": "Biogen CEO: We are at that inflection point where we are on a path to sustainable revenue growth"
              },
              {
                "id": 141950533,
                "url": "https://finnhub.io/api/news?id=c846e659349dab3d62d3d6577e64f8a483aba13607264797af9de8b6bf3383f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "FAIRFIELD, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- With just two days remaining before registration closes for HMG Strategy's 18th Annual Boston C-Level Technology Leadership Summit, qualified technology executives are encouraged to secure their seats now while limited seating remains available. The September 10 summit at The Harvard Club of Boston will bring together CIOs, CISOs, CTOs, Chief Digital Officers, Chief AI Officers and other senior technology leaders to discuss AI governance, Agen",
                "category": "company",
                "datetime": 1788877800,
                "headline": "Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit"
              },
              {
                "id": 141949974,
                "url": "https://finnhub.io/api/news?id=b2ec4341f3666dff5619e2b1d8bf38bc580c8ddb9dd8a17f52bb9771272207d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.",
                "category": "company",
                "datetime": 1788870420,
                "headline": "Lilly Builds Neuroscience into a New Long-Term Growth Driver"
              },
              {
                "id": 141447114,
                "url": "https://finnhub.io/api/news?id=19cc0111de45222b07fea8c7ddc3251f389d9dd11012f28e382b5180f973e17e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.",
                "category": "company",
                "datetime": 1788538380,
                "headline": "This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging."
              },
              {
                "id": 141438124,
                "url": "https://finnhub.io/api/news?id=4e483a3a1aad52a91180819ce46152d01ce7400fb0619f99548b670261024fe6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535806,
                "headline": "Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141408000,
                "url": "https://finnhub.io/api/news?id=07c91159a0c1171b678e371099f813e89feca5cf4ca2921069e9eddbbf202aeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...",
                "category": "company",
                "datetime": 1788496719,
                "headline": "Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?"
              },
              {
                "id": 141449953,
                "url": "https://finnhub.io/api/news?id=77f60339f8a0629d4fda7bf314e528dd31da98f7de685357d74ea3c5a43069bc",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced presentations",
                "category": "company",
                "datetime": 1788494412,
                "headline": "Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study"
              },
              {
                "id": 141406948,
                "url": "https://finnhub.io/api/news?id=6daf4bb5d4d1e052e138c0e313c0bd537696e56ab3f8a930a79da3ce86f46f60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BEDFORD, Mass. & CAMBRIDGE, Mass., September 03, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. Drave",
                "category": "company",
                "datetime": 1788478200,
                "headline": "Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)"
              },
              {
                "id": 141406186,
                "url": "https://finnhub.io/api/news?id=4c0048bde7b9e0643102d1df470e82b131b4c856156f52b33398160ca46d2f56",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Piper Sandler  analyst David Amsellem   reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.",
                "category": "company",
                "datetime": 1788442334,
                "headline": "Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245"
              },
              {
                "id": 141397461,
                "url": "https://finnhub.io/api/news?id=eb28a911a812ba2af9d8b179d4f4eed9a7ee9fcb76668966482c6da35263a38d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...",
                "category": "company",
                "datetime": 1788433589,
                "headline": "Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients"
              },
              {
                "id": 141406187,
                "url": "https://finnhub.io/api/news?id=533284683a477d1886426f3273a6f2bf4bb23892bd5451d219545aacdfc3683f",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the",
                "category": "company",
                "datetime": 1788408364,
                "headline": "Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment"
              },
              {
                "id": 141394955,
                "url": "https://finnhub.io/api/news?id=4a2a5cb4954bec9caced33087f4328d7d8a8dc43caefa2abf22fa8bf864604fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative DiseaseTOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (Chinese trademark: 乐意保®",
                "category": "company",
                "datetime": 1788408000,
                "headline": "LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China"
              },
              {
                "id": 141394954,
                "url": "https://finnhub.io/api/news?id=524fbdbda91a95f14d9f786fac930f2f05cbfe9c30cd36950b12849b6e72bdd1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track...",
                "category": "company",
                "datetime": 1788405959,
                "headline": "Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data"
              },
              {
                "id": 141379819,
                "url": "https://finnhub.io/api/news?id=a64fdd4280f1952b130f8c25d1558be0be050e099e1a656cc74a708d86298213",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366612,
                "headline": "Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?"
              },
              {
                "id": 141377242,
                "url": "https://finnhub.io/api/news?id=defda5ae25192c577dc34362b616a6cb78f5530085da1d35dd943ffd5f65d1af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026. The deal lands just over a week after the company posted a second-quarter beat that sent shares up nearly 5% on July 29. Together, the two moments […]",
                "category": "company",
                "datetime": 1788338886,
                "headline": "Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet"
              },
              {
                "id": 141364577,
                "url": "https://finnhub.io/api/news?id=505e816fdd144c6d926d117e23337e5a43dfca39a7daf531d6a3e4b58f74a732",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. The g",
                "category": "company",
                "datetime": 1788265800,
                "headline": "Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)"
              },
              {
                "id": 141368768,
                "url": "https://finnhub.io/api/news?id=305dda4a0c73f48d2f8dcef5a7f41edd755d258012197326054a6cf78c69f825",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced",
                "category": "company",
                "datetime": 1788247909,
                "headline": "Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress"
              },
              {
                "id": 141364575,
                "url": "https://finnhub.io/api/news?id=42d4c706c99f1f8be8446a820306716e516e9fe5e80c23a5d026273bc8aa298d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "An Important Step Forward for Access to LEQEMBI® for Eligible Patients in CanadaTOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of LEQEMBI® (lecanemab) for eligible patients in Canada living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (early AD). The final recommendation follows a r",
                "category": "company",
                "datetime": 1788222600,
                "headline": "Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease"
              },
              {
                "id": 141364578,
                "url": "https://finnhub.io/api/news?id=db1dc8bd97bef642bf3b08ebd399985594b48b71463b04394befe22f506dafbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]",
                "category": "company",
                "datetime": 1788101107,
                "headline": "Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks"
              },
              {
                "id": 141364572,
                "url": "https://finnhub.io/api/news?id=96292ea7f36033259878043ccf8aaadc836dcd4c68f80e3e939c8db3da56d144",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1787934624,
                "headline": "Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?"
              },
              {
                "id": 141360949,
                "url": "https://finnhub.io/api/news?id=db3938b666fed616eb0e253bbc6d4bf903231e7634103b3b89e617a8cca475b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.",
                "category": "company",
                "datetime": 1787844540,
                "headline": "FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now"
              },
              {
                "id": 141329630,
                "url": "https://finnhub.io/api/news?id=99da051c636022f784fa3e1396caa6ac59d1144555a9bb4f821808cefd922e11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Veeva Systems Inc (VEEV) reports $928 million in revenue and best-ever CRM performance, with Veeva Falcon AI gaining traction.",
                "category": "company",
                "datetime": 1787806883,
                "headline": "Veeva Systems Inc (VEEV) (Q2 2027) Earnings Call Highlights: Record CRM Quarter and AI Momentum ..."
              },
              {
                "id": 141329625,
                "url": "https://finnhub.io/api/news?id=95da78f240145b001517572b2bbcf2ef23b024c1059093434d3ab32af2a97dde",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment",
                "category": "company",
                "datetime": 1787785459,
                "headline": "Veeva Systems Q2 Earnings Call Highlights"
              },
              {
                "id": 141322438,
                "url": "https://finnhub.io/api/news?id=5b89a111c396ce77d686a5f752a6b55a41ab4baa4c092d77332afe86e3a63eb8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991654/image_2192991654.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.",
                "category": "company",
                "datetime": 1787731357,
                "headline": "TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)"
              },
              {
                "id": 141329623,
                "url": "https://finnhub.io/api/news?id=fe546552a0c8ef5e8d86a5751f5b4a949d1e90cfe0144073a4836877094a1668",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Veeva Systems' (VEEV) Vault CRM has cemented its position as the clear market leader in life science",
                "category": "company",
                "datetime": 1787684379,
                "headline": "Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist Says"
              },
              {
                "id": 141329614,
                "url": "https://finnhub.io/api/news?id=15b14cc122e7278df19a5f71f7a060941112438e995ca19289366a9eef9bddee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 14.4% to $218.22 per share while the index has gained 10.5%.",
                "category": "company",
                "datetime": 1787668724,
                "headline": "3 Reasons to Sell BIIB and 1 Stock to Buy Instead"
              },
              {
                "id": 141329615,
                "url": "https://finnhub.io/api/news?id=721e9b201db79e46758bc847c1b7f8c6029ee20dfbec54156c84fb750892e7aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Veeva Systems (NYSE: VEEV) today announced that Biogen has committed to Veeva Vault CRM globally.",
                "category": "company",
                "datetime": 1787655780,
                "headline": "Veeva Vault CRM Selected by Biogen"
              },
              {
                "id": 141319898,
                "url": "https://finnhub.io/api/news?id=a4b5defb267fb12e5d2132a4e7413039423eaa17cbbde99033eabac407a5cfa5",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.",
                "category": "company",
                "datetime": 1787650330,
                "headline": "RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260"
              },
              {
                "id": 141312689,
                "url": "https://finnhub.io/api/news?id=fb7a9580dde6983722a50c187fdeb63a1eb96a1cffd1fd789a5d3d0630fb0f5e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/847203194/image_847203194.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Acadia (ACAD) eyes Phase 2 remlifanserin Alzheimer’s psychosis results by September/October. Learn about the risks and revenue cushion from Daybue/Nuplazid.",
                "category": "company",
                "datetime": 1787600537,
                "headline": "Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple"
              },
              {
                "id": 141329626,
                "url": "https://finnhub.io/api/news?id=722f48211b99352e5bc8aeaf988d8d95b2017f05792356620d4849874b32355b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.)TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in the U.S. for initiation therapy for early Alzheimer’s disease (AD) in adults with mild cognitive impairment (MCI) or mild",
                "category": "company",
                "datetime": 1787573040,
                "headline": "LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease"
              },
              {
                "id": 141329627,
                "url": "https://finnhub.io/api/news?id=4b18edd2d8ef90a84bf72d7b9a38bcd4d32d02c6b84364440d50f3a9a8f6437a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in the U.S. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD. MCI due to AD is the earliest symptomatic stage of AD and can appear with subtle symptoms such as forgetfulness, confusion, or feeling at a loss for wor",
                "category": "company",
                "datetime": 1787572800,
                "headline": "LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease"
              },
              {
                "id": 141311516,
                "url": "https://finnhub.io/api/news?id=453496ef3cec1449dcd08558ba9c38adc6a31913365080ffa85a61d2c7d372b8",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in the U.S. for initiation therapy for early",
                "category": "company",
                "datetime": 1787558882,
                "headline": "Eisai And Biogen Announce Once Weekly Lecanemab-Irmb Subcutaneous Injection Is Now Available In U.S. For Initiation Therapy For Early Alzheimer’s Disease"
              },
              {
                "id": 141291858,
                "url": "https://finnhub.io/api/news?id=8ba28b3ef62591be53bd1267edb3588386fb93f48e84c11e7fd4e7edc819225a",
                "image": "",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "",
                "category": "company",
                "datetime": 1787390100,
                "headline": "TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors"
              },
              {
                "id": 141283040,
                "url": "https://finnhub.io/api/news?id=04014bc83df161e7f0b6800ceedd32afeed42773d4152055002ca69c2a5b6820",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. See our latest analysis for Biogen. Biogen's recent guidance upgrade comes after a period of renewed momentum, with the share price at US$214.35 and a 30 day share price return of about 8%, while the 1 year total shareholder return of around 54% contrasts with weaker 3 and 5 year total shareholder returns. This...",
                "category": "company",
                "datetime": 1787335779,
                "headline": "Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?"
              },
              {
                "id": 141283041,
                "url": "https://finnhub.io/api/news?id=b2e149fa6cfa0bb8923289db5380e452ecc38c942fc78fbc0bd6688fe7eaa233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio. This improved outlook, combined with investor attention on five upcoming Phase 3 readouts in lupus, transplant, and rare disease programs, has become a central focus in reassessing the company’s long-term profile. Next, we’ll examine how Biogen’s higher earnings guidance and advancing...",
                "category": "company",
                "datetime": 1787321617,
                "headline": "What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders"
              },
              {
                "id": 141283042,
                "url": "https://finnhub.io/api/news?id=86ac08017b0015a1ee7fbf30bb178d8373077092a3104214444db62caf4575a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.",
                "category": "company",
                "datetime": 1787238720,
                "headline": "Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?"
              },
              {
                "id": 141283043,
                "url": "https://finnhub.io/api/news?id=64f20baeaa17bfe1617877ac141acf21580bb59034e357a745352f1842572a5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen has notably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1787232624,
                "headline": "Is Wall Street Bullish or Bearish on Biogen Stock?"
              },
              {
                "id": 141278190,
                "url": "https://finnhub.io/api/news?id=bd31c4f774a8001880ac335a7929b8583da52983043d51e50f7a2be5384202a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1787160756,
                "headline": "Real Parkinson’s Disease Hope from Jupiter Neurosciences"
              },
              {
                "id": 141237366,
                "url": "https://finnhub.io/api/news?id=7520059c1e635c3a1db5a71abc23c482a4e538243e4691dbd434400fd30c87ea",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Biogen (BIIB) flashes a perfect technical rating and strong breakout setup, with a proposed entry at $215.61 and defined stop.",
                "category": "company",
                "datetime": 1786965108,
                "headline": "Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating"
              },
              {
                "id": 141206518,
                "url": "https://finnhub.io/api/news?id=9069d19d991acf04b9fca1c8a243ae50a474fe8d50a62762c1f60f1f800987d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.",
                "category": "company",
                "datetime": 1786629121,
                "headline": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation"
              },
              {
                "id": 141220042,
                "url": "https://finnhub.io/api/news?id=6126f4a3598717ae72957a00daec419da16ec28cdf3b4b54ad6be6e2ceb84f3a",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Wolfe Research  analyst Alexandria Hammond   upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.",
                "category": "company",
                "datetime": 1786627086,
                "headline": "Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 44,
            "discarded_article_count": 35
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.8,
        "grade": "較差",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.5,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 774663.3333333334,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 716400,
              "avg_vol_20": 704985,
              "avg_vol_30": 774663.3333333334,
              "range_pct_10": 0.07770616869156297,
              "range_pct_20": 0.08374020802670624,
              "range_pct_30": 0.12077383137845088,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9247888329984207,
              "dist_to_20d_high": 0.038529627989371186,
              "down_shrink_days": 4,
              "breakout_level_20d": 225.8,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.6434023646071704
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.6290648259297638,
              "turnoverUsdM": 189.20417841507,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BIIB",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 205.6846,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 5.3,
            "take_profit_price": 229.9328,
            "target_multiplier": 1.9,
            "technical_strength": 1.78,
            "take_profit_percent": 5.9
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.2581296518595275,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.BIIB",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 5.7077,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.63
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 7.18
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1358
    },
    "kdj": {
      "d": 44.72,
      "j": 32.2,
      "k": 40.54,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 48.85
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 4112807,
      "recentSlope": 23320.7,
      "previousSlope": 264970
    },
    "rsi": 50.41,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 224.8026,
      "position": "SAR喺價上",
      "distancePct": 3.55,
      "previousTrend": "下降"
    },
    "ma50": 209.473,
    "macd": {
      "macd": 1.9821277557400094,
      "trend": "中性偏多",
      "signal": 2.8992762351960657,
      "histogram": -0.9171484794560563
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 6,
      "value": 216.8554,
      "position": "連續1-2日>VWAP",
      "consecutiveAbove": 1
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.24,
      "score": 6,
      "avgVolume": 705555,
      "currentVolume": 871507
    },
    "derived": {
      "ma20": 217.032,
      "ma50": 209.473,
      "prevClose": 215.43,
      "avgVolume10": 753821,
      "avgVolume20": 705555,
      "changePercent": 0.78,
      "avgVolumeForScore": 705555
    },
    "ma_cross": {
      "ma20": 217.032,
      "ma50": 209.473,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 216.7095,
      "prevMa50": 209.3258,
      "spreadPct": 3.61,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 208.2969,
      "upper": 225.7671,
      "position": "上半部"
    },
    "rsi_short": 37.34,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.24
    }
  }
}

{
  "close": 217.1,
  "volume": 871507,
  "changePercent": 0.78
}